Cover Image
Market Research Report
Product code
1031966

Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026

Published: | KuicK Research | 150 Pages | Delivery time: 1-2 business days

Price

Back to Top
Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026
Published: October 12, 2021
KuicK Research
Content info: 150 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

“Global PDGFR Inhibitors Market, Drug Sales & Clinical Trials Insight 2026 Report Analysis & Data” Highlights:

  • Research Methodology
  • Global & Regional Market Analysis
  • Global PDGFR Inhibitors Market Opportunity Assessment: > USD 4 Billion
  • Market & Drug Sales Insight 2020 Till 2026
  • Approved Drug In Market: 2 (Lartruvo & Ayvakit)
  • Approved PGDFR Drug Patent, Price & Sales insight 2020 Till 2026
  • Future market Assessment By Indication & Region Till 2026
  • Ongoing Clinical Trials Assessment by Status, Phase & Region
  • Key Market Dynamics
  • Competitor Landscape

Platelet derived growth factor (PDGF) are the members of growth factor receptors which are found to be overexpressed in many cancers, correlating with reduced overall survival. In some cancer types, PDGF receptors are expressed on non-cancerous cells of the tumor microenvironment or tumor stroma that are able to crosstalk with cancer and thus have critical role in the development of cancer. Over the time, it has emerged out to be an important target for the drug therapies intended for treatment wide range of cancers.

Avapritinib sold under brand name Ayvakit is the first approved PDGFR inhibitor available in market. The drug was developed by Blueprint Medicines and is mainly indicated for the treatment of gastrointestinal tumors (GIST) and mastocytosis. The FDA approval of Ayvakit represents a major breakthrough in the treatment of rare GIST. Since it introduction into the market, the drug has shown high adoption rates among patients worldwide. The rise in prevalence of cancer and high medical needs for targeted therapy associated with increasing awareness regarding the availability of drug will further enhance its growth in market for next few years.

In the same year, Ripretinib sold under brand name Qinlcok has also gained approval. The drug is developed by Deciphera Pharmaceuticals and is indicated for the treatment of gastrointestinal tumors. <>In short span of time, the drug has shown robust sales in the global market. Owing to its high specificity towards PDGFR and ability to target broad spectrum of kinases, it is expected that the drug will dominate the overall PDGFR inhibitor market in coming years. Although the market is poised to growth in coming years but several factors limits their growth in market. The high cost of cancer therapy is one of the major limiting factors which will restrict the growth of market in coming years.

Presently, several companies including well-established players and new entrants are actively engaged in developing PGFR inhibitors for a wide range of disease indications. Innovation in this field is mostly focused on improving the therapeutic efficacy, safety, and overall survival rate. This sector has particularly gained significant attention from private and public investors, which have extended their financial support to capable developer companies. The market also witnessed substantial partnership activity over the last few years.

In coming years, the global market will witness significant rise in the prevalence of cancers attributing to several factors including rising geriatric population, smoking, drinking, physical inactivity, and poor diet. This will increase the demand of targeted therapies, thus driving the growth of PDGFR inhibitor market. In addition to two approved drugs, the pharmaceutical companies have developed several potential PGFR inhibitors including Crenolanib, Tovetumab, Seralutinib, ARRY-768, CP-673451, and MTLH001 which are expected to enter the market during the forecast period, thus boosting the growth of market.

As per report findings, the global PDGFR inhibitor market will grow with CAGR of 92% and is expected to reach around US$ 4 Billion by 2026. The high growth in the market can be justified by the extensive research and development in this sector and high adoption rates of approved drugs. In addition to this, the rising initiative by government and the development of favorable reimbursement policies will also ensure the high uptake of the drug in the market. Regionally, US is expected to dominate the market owing to large target population base, increasing adoption rates to novel therapies, and high concentration of pharmaceutical companies which actively indulge in research and development sector. Apart from this, Asia-Pacific region is also expected to exhibit high CAGR rates due to increased healthcare spending and presence of several untapped opportunities.
Table of Contents

Table of Contents

1. Introduction to PDGFR Inhibitors

  • 1.1. Overview
  • 1.2. Evolution of PDGFR Inhibitors

2. PDGFR Inhibitors - Mechanism of Action

  • 2.1. General Functions & Mechanism
  • 2.2. Approved Drugs Mechanism of Action

3. PDGFR Potential Target for Leading Pathological Conditions

4. Role of PDGFR Inhibitors in Cancer

5. Global PDGFR Inhibitors Clinical Trials Insight

  • 5.1. By Phase
  • 5.2. By Development Status
  • 5.3. By Region

6. Global PDGFR Inhibitor Market Insight

  • 6.1. Market Overview
  • 6.2. Current Market Scenario

7. PDGFR Inhibitor Regional Market Analysis

  • 7.1. US
  • 7.2. Europe
  • 7.3. China
  • 7.4. Japan
  • 7.5. ROW

8. PDGFR Inhibitor Market Opportunity By Indication

  • 8.1. Gastrointestinal Stromal Tumors
  • 8.2. Glioma
  • 8.3. Colorectal Cancer
  • 8.4. Leukemia
  • 8.5. Lung Cancer

9. Lartruvo (Olaratumab) 1st Approved PDGFR Inhibitor (2016) & Market Withdrawal (2019)

  • 9.1. Overview
  • 9.2. Dosage, Price & Sales Analysis

10. Ayvakit (Avapritinib) 2ND Approved PDGFR Inhibitor (2020)

  • 10.1. Overview
  • 10.2. Patents & Assignees

11. Ayvakit Commercial Insight

  • 11.1. Price & Dosage
  • 11.2. Sales Analysis

12. Qinlock (Ripretinib) 3rd Approved PDGFR Inhibitor (2020)

  • 12.1. Overview
  • 12.2. Patents & Assignees

13. Qinlock Commercial Insight

  • 13.1. Price & Dosage
  • 13.2. Sales Analysis

14. PDGFR Inhibitors Sales Forecast 2026

  • 14.1. Ayvakit Sales Forecast
  • 14.2. Qinlock Sales Forecast

15. PDGFR Inhibitor Future Market Perspectives

16. Global PDGFR Inhibitors Market Dynamics

  • 16.1. Market Drivers
  • 16.2. Market Challenges

17. Competitive Landscape

  • 17.1. Arog Pharmaceuticals, Inc
  • 17.2. AstraZeneca
  • 17.3. Bayer
  • 17.4. Blueprint Medicine
  • 17.5. Boehringer Ingelheim
  • 17.6. Clovis Oncology
  • 17.7. Deciphera Pharmaceuticals
  • 17.8. Eli Lilly
  • 17.9. Gilead Sciences
  • 17.10. Pfizer
  • 17.11. Tyrogenex
  • 17.12. Zai Lab

List of Tables

  • Table 4-1: Frequency of PDGFR by Cancer Types
  • Table 8-1: Global - Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in GIST, 2021 - 2026
  • Table 8-2: Global - Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Glioma, 2021 - 2026
  • Table 8-3: Global - Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Metastatic Colorectal Cancer, 2021 - 2026
  • Table 8-4: Global - Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Acute Myeloid Leukemia, 2021 - 2026
  • Table 8-5: Global - Expected Adoption Rate (Number of Patients) of PDGFR Inhibitors in Lung Cancer, 2021 - 2026

List of Figures

  • Figure 1-1: Evolution of PDGFR Inhibitors
  • Figure 2-1: PDGFR's Pathway, Receptors, Ligands & Functions
  • Figure 2-2: PDGFR Stimulated Effectors, Biomarkers & Cell Signaling Pathways
  • Figure 2-3: PDGFR Inhibitors - Mechanism of Action
  • Figure 2-4: Ayvakit - Mechanism of Action
  • Figure 2-5: Qinlok - Mechanism of Action
  • Figure 2-6: Lartruvo - Mechanism of Action
  • Figure 3-1: Role of PDGFR Inhibitors in Neurological Disorders
  • Figure 3-2: Potential Role of PDGFR Inhibitors in Asthma
  • Figure 4-1: PDGF Signaling in Cancer Progression
  • Figure 5-1: Global - Number of PDGFR Inhibitors Related Clinical Trials by Phase, October'2021
  • Figure 5-2: Global - PDGFR Inhibitors Related Clinical Trials by Phase (%), October'2021
  • Figure 5-3: Global - Number of PDGFR Inhibitors Related Clinical Trials by Development Status, October'2021
  • Figure 5-4: Global - Number of PDGFR Inhibitors Related Clinical Trials by Development Status (%), October'2021
  • Figure 5-5: Global - Number of PDGFR Inhibitors Related Clinical Trials by Region, October'2021
  • Figure 6-1: Global - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 6-2: Global - PDGFR Inhibitor Market by Product (%), 2020
  • Figure 6-3: Global - PDGFR Inhibitor Market by Product (%), H1'2021
  • Figure 6-4: Global - PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
  • Figure 6-5: PDGFR Inhibitor - Market by Region (US$ Million), 2020
  • Figure 6-6: PDGFR Inhibitor - Market by Region (%), 2020
  • Figure 6-7: PDGFR Inhibitor - Market by Region (US$ Million), H1'2021
  • Figure 6-8: PDGFR Inhibitor - Market by Region (%), H1'2021
  • Figure 7-1: US - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 7-2: PDGFR Inhibitor Market - US vs. ROW (US$ Million), 2020
  • Figure 7-3: PDGFR Inhibitor Market - US vs. ROW (%), 2020
  • Figure 7-4: PDGFR Inhibitor Market - US vs. ROW (US$ Million), H1'2021
  • Figure 7-5: PDGFR Inhibitor Market - US vs. ROW (%), H1'2021
  • Figure 7-6: US - PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
  • Figure 7-7: Europe - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 7-8: Europe - Cancer Incidences by Country (Million), 2020
  • Figure 7-9: PDGFR Inhibitor Market - Europe vs. ROW (US$ Million), 2020
  • Figure 7-10: PDGFR Inhibitor Market - Europe vs. ROW (%), 2020
  • Figure 7-11: Europe - PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
  • Figure 7-12: China - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 7-13: China - PDGFR Inhibitor Market Size (US$ Million), 2021 - 2026
  • Figure 7-14: Japan - Cancer Incidences & Deaths (Million), 2020 & 2025
  • Figure 7-15: Japan - PDGFR Inhibitor Market Size (US$ Million), 2022 - 2026
  • Figure 7-16: Cancer - Incidences by Region, 2020
  • Figure 7-17: ROW - PDGFR Inhibitor Market Size (US$ Million), 2020 - 2026
  • Figure 8-1: Global - Estimated GIST Cancer Cases, 2020 - 2026
  • Figure 8-2: Global - PDGFR Inhibitor Market Opportunity in GIST by 5% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-3: Global - PDGFR Inhibitor Market Opportunity in GIST by 10% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-4: Global - PDGFR Inhibitor Market Opportunity in GIST by 15% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-5: Global - PDGFR Inhibitor Market Opportunity in GIST by 20% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-6: Global - PDGFR Inhibitor Market Opportunity in GIST by 25% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-7: Global - PDGFR Inhibitor Market Opportunity in GIST by 30% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-8: Global - PDGFR Inhibitor Market Opportunity in GIST by 35% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-9: Global - PDGFR Inhibitor Market Opportunity in GIST by 40% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-10: Global - PDGFR Inhibitor Market Opportunity in GIST by 45% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-11: Global - PDGFR Inhibitor Market Opportunity in GIST by 50% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-12: Global - Estimated Glioma Cancer Cases, 2020 - 2026
  • Figure 8-13: Global - PDGFR Inhibitor Market Opportunity in Glioma by 2% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-14: Global - PDGFR Inhibitor Market Opportunity in Glioma by 4% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-15: Global - PDGFR Inhibitor Market Opportunity in Glioma by 6% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-16: Global - PDGFR Inhibitor Market Opportunity in Glioma by 8% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-17: Global - PDGFR Inhibitor Market Opportunity in Glioma by 10% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-18: Global - PDGFR Inhibitor Market Opportunity in Glioma by 12% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-19: Global - PDGFR Inhibitor Market Opportunity in Glioma by 14% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-20: Global - PDGFR Inhibitor Market Opportunity in Glioma by 16% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-21: Global - PDGFR Inhibitor Market Opportunity in Glioma by 18% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-22: Global - PDGFR Inhibitor Market Opportunity in Glioma by 20% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-23: Global - Estimated Colorectal Cancer Cases, 2020-2026
  • Figure 8-24: Global - Estimated Metastatic Colorectal Cancer Cases, 2020-2026
  • Figure 8-25: Global - PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 1% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-26: Global - PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 2% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-27: Global - PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 3% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-28: Global - PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 4% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-29: Global - PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 5% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-30: Global - PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 6% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-31: Global - PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 7% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-32: Global - PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 8% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-33: Global - PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 9% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-34: Global - PDGFR Inhibitor Market Opportunity in Colorectal Cancer by 10% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-35: Global - Estimated Leukemia Cancer Cases, 2020 - 2026
  • Figure 8-36: Global - Estimated Acute Myeloid Leukemia Cancer Cases, 2020 - 2026
  • Figure 8-37: Global - PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 1% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-38: Global - PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 2% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-39: Global - PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 3% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-40: Global - PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 4% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-41: Global - PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 5% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-42: Global - PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 6% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-43: Global - PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 7% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-44: Global - PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 8% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-45: Global - PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 9% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-46: Global - PDGFR Inhibitor Market Opportunity in Acute Myeloid Leukemia by 10% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-47: Global - Estimated Lung Cancer Cases, 2020 - 2026
  • Figure 8-48: Global - Estimated PDGFR Mutated Lung Cancer Cases, 2021 - 2026
  • Figure 8-49: Global - PDGFR Inhibitor Market Opportunity in Lung Cancer by 1% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-50: Global - PDGFR Inhibitor Market Opportunity in Lung Cancer by 2% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-51: Global - PDGFR Inhibitor Market Opportunity in Lung Cancer by 3% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-52: Global - PDGFR Inhibitor Market Opportunity in Lung Cancer by 4% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-53: Global - PDGFR Inhibitor Market Opportunity in Lung Cancer by 5% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-54: Global - PDGFR Inhibitor Market Opportunity in Lung Cancer by 6% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-55: Global - PDGFR Inhibitor Market Opportunity in Lung Cancer by 7% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-56: Global - PDGFR Inhibitor Market Opportunity in Lung Cancer by 8% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-57: Global - PDGFR Inhibitor Market Opportunity in Lung Cancer by 9% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 8-58: Global - PDGFR Inhibitor Market Opportunity in Lung Cancer by 10% Adoption Rate (US$ Million), 2021 - 2026
  • Figure 9-1: Lartruvo - Approval Year by Region
  • Figure 9-2: Lartruvo - FDA Approval & Orphan Designation Year
  • Figure 9-3: Lartruvo - Compound Patent & Biological Data Package Protection Expiration Year
  • Figure 9-4: Lartruvo - Market Approval & Withdrawal Year
  • Figure 9-5: Lartruvo - Price for 19ml Supply & Price per ml of Intravenous Solution (US$), October'2021
  • Figure 9-6: Lartruvo - Price for 50ml Supply & Price per ml of Intravenous Solution (US$), October'2021
  • Figure 9-7: Lartruvo - Average Cost of Single Dose & Single Treatment Cycle (US$), October'2021
  • Figure 9-8: Global - Lartruvo Annual Sales (US$ Million), 2017 & 2018
  • Figure 10-1: Ayvakit - Orphan Drug Designation by Region
  • Figure 10-2: US - Ayvakit FDA Approval Year by Indication
  • Figure 10-3: Ayvakit - Approval Year by Region
  • Figure 10-4: US - Avyakit Patent Approval & Expiration Year
  • Figure 11-1: US - Cost of Supply of 30 Tablets & Per Unit Cost of Ayvakit Oral Tablet (US$), October'2021
  • Figure 11-2: Europe - Cost of Supply of 30 Tablets & Per Unit Cost of Ayvakit Oral Tablet (Euro/US$), October'2021
  • Figure 11-3: Ayvakit - Recommended Initial & Reduced Dose in Patients with GIST (mg)
  • Figure 11-4: US - Average Cost of Daily, Monthly & Annual Treatment with Ayvakit (US$)
  • Figure 11-5: Global - Ayvakit Quarterly Sales (US$ Million), 2020
  • Figure 11-6: Global - Ayvakit Quarterly Sales (US$ Million), Q1 - Q3'2021
  • Figure 12-1: US - Qinlock Orphan Drug Designation & FDA Approval Year
  • Figure 12-2: Qinlock - Approval Year by Region
  • Figure 12-3: US - Qinlock Patent Approval & Expiration Year
  • Figure 12-4: Canada - Qinlock Patent Approval & Expiration Year
  • Figure 13-1: US - Cost of Supply of 90 Tablets & Per Unit Cost of Qinlock 50mg Oral Tablet (US$), October'2021
  • Figure 13-2: Qinlock - Recommended Initial & Reduced Dose in Patients with GIST (mg)
  • Figure 13-3: US - Average Cost of Daily, Monthly & Annual Treatment with Qinlock (US$)
  • Figure 13-4: Global - Qinlock Quarterly Sales (US$ Million), Q2-Q4'2020
  • Figure 13-5: US - Qinlock Quarterly Sales (US$ Million), Q2-Q4'2020
  • Figure 13-6: Qinlock Quarterly Sales by Region (US$ Million), Q2-Q4'2020
  • Figure 13-7: Qinlock Quarterly Sales by Region (%), Q2-Q4'2020
  • Figure 13-8: Global - Qinlock Quarterly Sales (US$ Million), Q1 & Q2'2021
  • Figure 13-9: US - Qinlock Quarterly Sales (US$ Million), Q1 & Q2'2021
  • Figure 13-10: Qinlock - Half Year Sales by Region (US$ Million), H1'2021
  • Figure 13-11: Qinlock - Half Year Sales by Region (%), H1'2021
  • Figure 14-1: Global - Ayvakit Sales Forecast (US$ Million), 2021 - 2026
  • Figure 14-2: Global - Qinlock Sales Forecast (US$ Million), 2021 - 2026
  • Figure 14-3: US - Qinlock Sales Forecast (US$ Million), 2021 - 2026
  • Figure 14-4: ROW - Qinlock Sales Forecast (US$ Million), 2021 - 2026
  • Figure 16-1: Global PDGFR Inhibitors Market Drivers
  • Figure 16-2: Challenges for Global PDGFR Inhibitors Market
  • Figure 16-3: US - Annual Treatment Cost Comparison of PDGRF Inhibitors with Other Treatments (US$), October'2021